Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Neuroendocrine tumours (NETs) are neoplasms that arise from neuroendocrine cells.
Neuroendocrine cells and their tumours can secrete a wide range of amines and …

Human cancer cells overexpress many peptide receptors as molecular targets.
Radiolabeled peptides that bind with high affinity and specificity to the receptors on tumor …

Biomarkers have been the mainstay in the diagnosis and follow-up of patients with
neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory …

Preoperative localization of insulinoma is a clinical dilemma. We aimed to investigate
whether glucagon-like peptide-1 receptor (GLP-1R) PET/CT with 68Ga-NOTA-MAL-cys40 …

Neuroendocrine tumors have shown rising incidence mainly due to higher clinical
awareness and better diagnostic tools over the last 30 years. Functional imaging of …

Receptor targeting with radiolabelled peptides has become very important in nuclear
medicine and oncology in the past few years. The overexpression of many peptide receptors …

Receptor targeting with radiolabeled peptides has become an important topic, particularly in
nuclear oncology. Strong research efforts are under way in radiopharmaceutical science …

ENETS consensus recommendations for the standards of care in neuroendocrine
neoplasms (NEN) concerning follow-up and documentation are considered in this review …

Background Small benign insulinomas are hard to localise, leading to difficulties in planning
of surgical interventions. We aimed to prospectively assess the insulinoma detection rate of …